MT High Tech Business Alliance

View Original

Montana Biotech Companies to Watch 2024

By Melissa Paulsen

Graphic by Nate Gorin.

May 30, 2024

Since 2017, the Montana High Tech Business Alliance has annually showcased top tech companies in Montana. This year, in partnership with the Montana Bioscience Cluster Initiative, we present the 2024 Montana Biotech Companies to Watch (see the first Biotech 2020 list). These companies are leading the charge in biotech innovation, from improving healthcare for underserved populations to using AI for remote health monitoring and revolutionizing drug discovery with advanced tools.

Key Industry Trends:

  1. Female Entrepreneurship: Five of the six firms were founded or led by women, underscoring growing gender diversity in Montana’s entrepreneurial ecosystem.

  2. Bozeman - A Biotech Hub: Five of the six companies are based in Bozeman, with two originating as spin-offs from Montana State University, highlighting Bozeman’s growing importance in the biotech sector. 

  3. Grant Success: Three firms secured SBIR/STTR grants, showcasing Montana’s high success rate in these competitive federal programs. From 2012 - 2021, Montana's success rate was 18%, surpassing the national average of 16%.

  4. Bootstrapping Success: Two companies self-funded their ventures, reflecting Montana’s entrepreneurial history of bootstrapping.

Selection Criteria:

Nominations came from industry partners across Montana, including MonTEC, the Montana Bioscience Alliance, the Missoula Economic Partnership, and others. The six finalists were chosen based on:

  • Significant revenue growth or high-growth sector involvement

  • Potential to launch impactful products or services

  • Valuable intellectual property ownership or development

  • Prospects of acquiring major clients or entering new markets

  • Expansion plans or significant job creation in the next year

  • Management teams led by experienced entrepreneurs or top experts

These innovative businesses are not only advancing the life sciences but also enriching life in Montana.

Here are the 2024 Montana Biotech Companies to Watch:

See this content in the original post

IntelligHealth

See this content in the original post

IntelligHealth’s AI-driven technology platform objectively assesses a patient’s condition using real-time monitoring data and remote health-monitoring technologies.

Location: Bozeman

What They Do: Use AI-driven data analytics and remote health monitoring systems to detect, classify, and monitor respiratory diseases.

Why We’re Watching Them: The need for remote health technologies and patient monitoring has been on the rise in both urban and rural areas across the nation since the COVID-19 pandemic. IntelligHealth is meeting the increased demand through its AI-driven algorithm that detects, classifies, and monitors respiratory diseases through wearable technology (such as smart watches) and FDA-approved medical devices to help clinicians efficiently triage their patients without increasing their workload.

Within ten minutes IntelligHealth’s algorithm identifies the respiratory condition afflicting a patient and can alert providers securely. From the comfort of their home, the patient can send data and notes through their smartphone app directly to their medical provider. Additional uses for the system include revealing health patterns, creating alerts, or serving as a valuable decision tool for clinicians. Patients can also send updates monthly, weekly, or daily depending on their risk level.

Empathy drives co-founder Laura Stanley, Ph.D., and her work behind IntelligHealth. During her pregnancy, Dr. Stanley developed a heart arrhythmia that remains with her today. Her experience wearing heart monitors for more than eight years has helped her to design user-friendly devices.

“It allows you to have that empathy,” Stanley said. “You have to get in the shoes of your patient, whoever’s suffering, and that’s hard to do. I don’t know if I could have done that had I not had this heart condition.”

Return to Top


See this content in the original post

KLEO

Location: Missoula

What they do: Support the research and development of products that improve the health and well-being of our communities and challenge the traditional thinking of the MedTech commercialization process by providing boutique clinical, regulatory, and market access services.

Why We’re Watching Them: KLEO provides high-quality consulting services and integrated expertise to the MedTech industry without massive overhead costs. The company supports all aspects of market entry for MedTech firms aiming to commercialize health innovations. 

With three full-time employees and independent contractors across the United States, KLEO offers a wide range of professional services, including clinical operations, data management, market access, regulatory affairs, and medical writing.

Founded in 2019, KLEO began as a data management firm analyzing large clinical trial datasets. However, after working on ad hoc consulting projects for medical device companies, founder Karen Brown realized the need for integrated expertise in the MedTech industry. Through bootstrapping, Brown rebranded the company as a global contract research organization. 

“In the last year and a half or so we really committed to bolstering what KLEO could do and growing into a full-service company,” Brown said. “Taking [KLEO’s] drive to bring clinical research and health innovation to underserved and minority populations and coupling it with experience in the industry [has] been really rewarding.”

Return to Top


Montana Molecular

See this content in the original post

Montana Molecular’s Red Down DAG Assay Kit.

Location: Bozeman

What They Do: Reduce the risk and cost of drug development with a live cell platform of fluorescent biosensors, gene delivery vectors, analytic tools, and services.

Why We’re Watching Them: Drug development is fraught with high costs and risks, especially with clinical trials ending in failure about 90% of the time. Montana Molecular addresses this challenge by enabling biotech companies and pharmaceutical firms to efficiently test their compounds in living cells that are relevant to disease. Montana Molecular’s proprietary platform enables observation of specific cellular responses and drug signaling pathways, and delivers high-quality, clinically relevant information early in development

Montana Molecular, a certified woman-owned business by the Women’s Business Enterprise National Council (WBENC), offers nearly 100 products and services, primarily for therapeutic drug development. Researchers worldwide also use these products to study basic cell biology as well as various diseases, including substance use disorders, asthma, cancer, obesity, and diabetes. 

Founder and CEO Anne Marie Quinn earned her master’s in public health from Yale University School of Medicine. She launched Montana Molecular in 2007 after working in the pharmaceutical industry and noticing the challenges of bringing new drugs to market.

“I noticed a disconnect in [drug development] decisions based on information that was acquired in artificial biochemical or chemical assays,” Quinn said. “There really wasn't any consideration of the biology of the drug until you got into animal testing, which is way down the line, after a lot of investment. It is so much more effective to test candidate drugs in a biological process, so that’s what drove the idea behind [Montana Molecular].”

Montana Molecular's integrated platform for drug discovery in living cells.

Return to Top


NanoMagnetic Solutions

See this content in the original post

Location: Bozeman

What they do: Develop advanced tools using force modulation to revolutionize preclinical drug discovery for brain diseases.

Why We’re Watching Them: NanoMagnetic Solutions manufactures cutting-edge research tools that mimic physiological forces in the human body, helping scientists generate more reliable preclinical drug discovery data for brain diseases. Their primary product is a 3-D-printed magnetic ring that attaches to standard 35-millimeter Petri dishes. This ring exerts a consistent magnetic field gradient over millions of cells, enabling alterations in cell structure and activity, and facilitating tissue engineering.

“The tool is really versatile and goes with every type of cell you want to grow in a Petri dish, but the big advantage is that you get an additional force signal into your standard tract testing approach,” said co-founder Dr. Anja Kunze.

Dr. Kunze’s post-doctoral brain tissue research served as the catalyst for NanoMagnetic Solutions. Encouraged to market the technology after exhibiting it at a science fair at Montana State University (MSU), Kunze and her two co-founders established the company in 2019 as a spin-off from the lab at MSU.

In 2020, NanoMagnetic Solutions placed second overall for traditional ventures in the Montana State University $50K Venture Capital Competition hosted by the Jake Jabs College of Business & Entrepreneurship. The company has raised approximately $42,000 to date between multiple grants from the National Science Foundation and a seed grant from MSU's Blackstone Launchpad. They have also filed three provisional patents through MSU’s Technology Transfer Office.

Return to Top


Titin KM Biomedical

See this content in the original post

Titin KM Biomedical’s Humero Tech C1 machine helps patients regain shoulder strength and recover quickly from injury.

Location: Bozeman

What They Do: Manufacture biomedical machines to diagnose debilitating shoulder injuries and assist with patient rehabilitation.

Why We’re Watching Them: Shoulder injuries are common, especially in athletics due to repeated and intense movements. Named after the protein found in skeletal muscle, Titin KM Biomedical (Titin) helps patients regain shoulder strength and recover quickly from injury with its groundbreaking Humero Tech C1 machine. 

Built-to-order at its 10,000-square-foot Bozeman facility, Titin’s Humero Tech C1 machine revolutionizes the recovery process. The machine uses sensors and mechanical technology to track a patient’s efforts through strength-based exercises, providing in-depth metrics to inform the next steps in their recovery. 

Co-founders Kole and Kam Mickolio, born and raised in Belgrade, Montana, have first-hand experience with severe injuries and the rehabilitation process. At 26, Kole suffered a stroke while studying biomedical engineering. After years of rehabilitation, Kole developed the idea for Titin during his second year of medical school at Dartmouth College. He earned his Master of Science in Molecular Medicine from Montana State University and is currently a radiology resident at Dartmouth. 

Kam Mickolio played professional baseball in the MLB and Japan until a rotator cuff injury while pitching for the Minnesota Twins cut his career short. With his extensive experience in shoulder injury and rehabilitation, Kam oversees the sales and marketing division of Titin. The brothers’ experiences led to the founding of Titin in 2020, along with their cousin, Chad Sukit, and Chief of Engineering Rory Maughan. 

Return to Top


The Toothpick Company / KUVU Bio Solutions

See this content in the original post

Location: Kenya and Bozeman

The Toothpick Company’s award-winning bioherbicide technology's active agent is a locally sourced host-specific fungus selected for high levels of excretion of specific amino acids. This innovation is poised to disrupt weed management globally, a $34 billion industry dominated by synthetic chemical herbicides. 

What they do: Develop natural biological herbicides to exterminate weeds threatening crop yields.

Why We’re Watching Them: Striga witchweed devastates staple crops across approximately 40 million farms in sub-Saharan Africa, leading to widespread malnutrition. The Toothpick Company combats this parasitic weed using selected strains of the fungus Fusarium oxysporum, (FOXY) to provide host-specific biological crop protection, eliminating the need for toxic synthetic chemical herbicides. 

In 2007, co-founder John Sands, a retired U.S. Navy surgeon, learned about the pernicious weed while volunteering in Kenya. He returned to the United States and enlisted his brother, Dr. David Sands, a plant pathologist and biotechnologist, to address malnutrition through crop protection. Dr. David Sands developed the biotechnology to prevent Striga through research at Montana State University (MSU) and in collaboration with scientists at the Kenya Agricultural and Livestock Research Organization. After receiving a Grand Challenges Exploration Grant from the Bill and Melinda Gates Foundation in 2013, the team conducted proof of concept trials in Western Kenya. With consistent results showing crop yield increases of 35-85%, the pilot social enterprise Toothpick Company was founded in 2018. 

Originally, the fungal strains were grown on toothpicks (hence the company name) that were used to make a live, fresh inoculum at the village level. This product received regulatory approval in 2021, making it one of the first bioherbicides to be commercialized in the world. In 2023, the second product iteration using the FOXY strains as a seed coating was approved, reducing the price by 60% and extending shelf life. The company will break even in 2025 and is currently expanding into Uganda. 

The team from Toothpick Company Ltd., headquartered in Kakamega, Kenya, celebrated the launch of the new seed coating product at a large stakeholder event in December 2023. In addition to co-founder Claire Sands Baker, women hold the three top positions (Managing Director, Head of Administration and Finance, and Scientist). 

The Toothpick Company has received various grants and participated in MSU’s Blackstone Launchpad 406Labs Accelerator, the UN World Food Program Innovation Accelerator, and the Stanford University Global Innovation Catalyst Go-To-Market Strategy course created specifically for African enterprises. It has gained major international recognition, including the 2024 Sankalp Africa Award, 2024 MassChallenge Alumni Award, and the 2021 UN Food Systems Summit Best Small Business Award. The Toothpick Company was also shortlisted for the 2023 Food Planet Prize and was a finalist for the Milken-Motsepe Prize in Agri-tech. The United Nations World Food Program and the German NGO Welthungerhilfe have the Toothpick Company listed in their innovation portfolios. 

Return to Top


About the Publisher: Launched in 2014, the Montana High Tech Business Alliance is a nonpartisan nonprofit association of more than 200 high tech and manufacturing companies and affiliates creating high-paying jobs in Montana. For more information, visit MTHighTech.org or subscribe to our newsletter.

About the Author: Melissa Paulsen is the communications coordinator for the Montana High Tech Business Alliance. She graduated from the University of Montana in 2022 with a BFA in creative writing and a minor in history.

About the Graphic Designer: Nathaniel Gorin is a former content creator intern for the Montana High Tech Business Alliance. He graduated from the University of Montana with a degree in marketing and creative writing.

See this content in the original post